AXITINIB IN SECOND AND FURTHER LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA (RCC): REAL WORLD DATA FROM 2 TEACHING HOSPITALS IN BIRMINGHAM (UK).
Cinzia Canipari, Farzana Haque, Ankit Jain, Emilio Porfiri.
Queen Elizabeth Hospital and City Hospital Birmingham, United Kingdom

BACKGROUND
Axitinib is a tyrosine kinase inhibitor (TKI) targeting VEGFR 1, 2 & 3 approved for the treatment of renal cell carcinoma (RCC) after the failure of sunitinib or cytokines. The efficacy of axitinib in real world setting has not been assessed. Here we report the outcomes of 52 RCC patients treated with axitinib in two teaching hospitals in Birmingham (UK) between April 2012 and January 2015.

METHODS
We collected: baseline clinical characteristics, demographics, laboratory and radiology reports, follow up data. Primary outcome of the study was overall survival (OS) which was calculated from the start of the treatment with axitinib, secondary outcomes were progression free survival (PFS) and response rate, estimated using RECIST criteria. Kaplan-Meier methods were used for OS and PFS analysis.

RESULTS
Median age of the 52 patients was 64 years (range 39-82). ECOG performance status was 0 in 27 (52%) patients, 1 in 18 (35%) patients and 2 in 7 (13%) patients. 8 (15 %) patients were classified as having good prognosis, 33 (63%) intermediate prognosis and 11 (22%) poor prognosis according to the Heng's prognostic classification. 37 (71.2%) patients received axitinib as 2nd line treatment, 22 after sunitinib and 15 after pazopanib. The remaining 15 (28.8%) had axitinib as 3rd or further line.

Median OS of the whole group of patients was 13.1 months (95% CI 9.5-16.7), PFS was 5.7 months (95% CI 2.3-9.1). Median OS of the patients who had axitinib as 2nd line (green) was 12.1 months (95% CI 10-14.4), PFS was 5 months (95% CI 0.3-6.7). Median OS of the 15 patients who had axitinib as 3rd or further line (blue) was 20.2 months (95% CI 4.8-35.6) and median PFS was 7.6 months (95% CI 0-184.)

CONCLUSIONS
Our results confirm the efficacy of axitinib in TKI pre-treated patients. Moreover, our data suggest that axitinib is also active after pazopanib and beyond the second line setting.